AR091567A1 - Preparacion liquida, metodo, kit de inyeccion - Google Patents
Preparacion liquida, metodo, kit de inyeccionInfo
- Publication number
- AR091567A1 AR091567A1 ARP130102255A AR091567A1 AR 091567 A1 AR091567 A1 AR 091567A1 AR P130102255 A ARP130102255 A AR P130102255A AR 091567 A1 AR091567 A1 AR 091567A1
- Authority
- AR
- Argentina
- Prior art keywords
- liquid preparation
- methylmethanamine
- pyrrol
- pyridin
- acid
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 9
- 239000007788 liquid Substances 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 2
- 238000002347 injection Methods 0.000 title 1
- 239000007924 injection Substances 0.000 title 1
- 150000007524 organic acids Chemical class 0.000 abstract 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 abstract 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 2
- GKYNXSVMESZZIF-UHFFFAOYSA-N 1-(4-fluoro-5-phenyl-1-pyridin-3-ylsulfonylpyrrol-3-yl)-n-methylmethanamine Chemical compound FC=1C(CNC)=CN(S(=O)(=O)C=2C=NC=CC=2)C=1C1=CC=CC=C1 GKYNXSVMESZZIF-UHFFFAOYSA-N 0.000 abstract 1
- JDCBSVKVFVIKHL-UHFFFAOYSA-N 1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(4-methylpyridin-2-yl)sulfonylpyrrol-3-yl]-n-methylmethanamine Chemical compound FC=1C(CNC)=CN(S(=O)(=O)C=2N=CC=C(C)C=2)C=1C1=CC=CN=C1F JDCBSVKVFVIKHL-UHFFFAOYSA-N 0.000 abstract 1
- YWPLCBMVGOFMDD-UHFFFAOYSA-N 1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-n-methylmethanamine Chemical compound FC=1C(CNC)=CN(S(=O)(=O)C=2C=NC=CC=2)C=1C1=CC=CN=C1F YWPLCBMVGOFMDD-UHFFFAOYSA-N 0.000 abstract 1
- GLTCPTOZHSIXQA-UHFFFAOYSA-N 1-[5-(2-fluorophenyl)-1-(6-methylpyridin-3-yl)sulfonylpyrrol-3-yl]-n-methylmethanamine Chemical compound C=1C=C(C)N=CC=1S(=O)(=O)N1C=C(CNC)C=C1C1=CC=CC=C1F GLTCPTOZHSIXQA-UHFFFAOYSA-N 0.000 abstract 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000005711 Benzoic acid Substances 0.000 abstract 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 abstract 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 abstract 1
- 150000001408 amides Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- 235000010233 benzoic acid Nutrition 0.000 abstract 1
- 229960004365 benzoic acid Drugs 0.000 abstract 1
- 229910001622 calcium bromide Inorganic materials 0.000 abstract 1
- 239000001110 calcium chloride Substances 0.000 abstract 1
- 229910001628 calcium chloride Inorganic materials 0.000 abstract 1
- WGEFECGEFUFIQW-UHFFFAOYSA-L calcium dibromide Chemical compound [Ca+2].[Br-].[Br-] WGEFECGEFUFIQW-UHFFFAOYSA-L 0.000 abstract 1
- 239000007795 chemical reaction product Substances 0.000 abstract 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 239000001530 fumaric acid Substances 0.000 abstract 1
- 229960002598 fumaric acid Drugs 0.000 abstract 1
- 235000011087 fumaric acid Nutrition 0.000 abstract 1
- 229910001629 magnesium chloride Inorganic materials 0.000 abstract 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
- 239000011976 maleic acid Substances 0.000 abstract 1
- 229940098895 maleic acid Drugs 0.000 abstract 1
- SRTTWNYIEACZDL-UHFFFAOYSA-N n-methyl-1-[5-(2-methylphenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]methanamine Chemical compound C=1C=CN=CC=1S(=O)(=O)N1C=C(CNC)C=C1C1=CC=CC=C1C SRTTWNYIEACZDL-UHFFFAOYSA-N 0.000 abstract 1
- RXQZPPFNPSUVQJ-UHFFFAOYSA-N n-methyl-1-[5-(4-methylthiophen-3-yl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]methanamine Chemical compound C=1C=CN=CC=1S(=O)(=O)N1C=C(CNC)C=C1C1=CSC=C1C RXQZPPFNPSUVQJ-UHFFFAOYSA-N 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 235000010199 sorbic acid Nutrition 0.000 abstract 1
- 239000004334 sorbic acid Substances 0.000 abstract 1
- 229940075582 sorbic acid Drugs 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01D—COMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
- C01D3/00—Halides of sodium, potassium or alkali metals in general
- C01D3/04—Chlorides
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01D—COMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
- C01D3/00—Halides of sodium, potassium or alkali metals in general
- C01D3/10—Bromides
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F11/00—Compounds of calcium, strontium, or barium
- C01F11/20—Halides
- C01F11/24—Chlorides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Materials Engineering (AREA)
- Geology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporcionan una preparación líquida en donde el principio farmacéuticamente activo es estabilizado, y un método estabilizante para ello. Una preparación líquida que comprende un principio farmacéuticamente activo con un grupo amino primario o secundario (en donde el grupo amino no constituye una parte de la estructura de amida), un ácido orgánico y una sal, que está sustancialmente libre de un producto de reacción del principio farmacéuticamente activo y el ácido orgánico. Reivindicación 5: La preparación líquida de acuerdo a la reivindicación 1, caracterizado porque el principio farmacéuticamente activo es un compuesto no peptídico. Reivindicación 8: La preparación líquida de acuerdo a la reivindicación 5, caracterizado porque el compuesto no peptídico es 1-{5-(2-fluorofenil)-1-[(6-metilpiridin-3-il)sulfonil]-1H-pirrol-3-il}-N-metilmetanamina, 1-[4-fluoro-5-fenil-1-(piridin-3-ilsulfonil)-1H-pirrol-3-il]-N-metilmetanamina, N-metil-1-[5-(4-metil-3-tienil)-1-(piridin-3-ilsulfonil)-1H-pirrol-3-il]metanamina, 1-[5-(2-fluorofenil)-1-(piridin-3-ilsulfonil)-1H-pirrol-3-il]-N-metilmetanamina, N-metil-1-[5-(2-metilfenil)-1-(piridin-3-ilsulfonil)-1H-pirrol-3-il]metanamina, 1-{4-fluoro-5-(2-fluoropiridin-3-il)-1-[(4-metilpiridin-2-il)sulfonil]-1H-pirrol-3-il}-N-metilmetanamina, o 1-[4-fluoro-5-(2-fluoropiridin-3-il)-1-(piridin-3-ilsulfonil)-1H-pirrol-3-il]-N-metilmetanamina. Reivindicación 11: La preparación líquida de acuerdo a la reivindicación 1, caracterizado porque donde el ácido orgánico es una o más clases seleccionadas del grupo que consiste en ácido ascórbico, ácido benzoico, ácido sórbico, ácido fumárico y ácido maleico. Reivindicación 14: La preparación líquida de acuerdo a la reivindicación 1, caracterizado porque la sal es una o más clases seleccionadas del grupo que consiste en cloruro de sodio, cloruro de calcio, cloruro de magnesio, bromuro de sodio y bromuro de calcio. Reivindicación 22: Una preparación liofilizada obtenida mediante la liofilización de la preparación líquida de acuerdo a la reivindicación 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012144750 | 2012-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091567A1 true AR091567A1 (es) | 2015-02-11 |
Family
ID=48795873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102255 AR091567A1 (es) | 2012-06-27 | 2013-06-26 | Preparacion liquida, metodo, kit de inyeccion |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20150165027A1 (es) |
| EP (1) | EP2866788B1 (es) |
| JP (1) | JP6216338B2 (es) |
| KR (1) | KR102206928B1 (es) |
| CN (3) | CN110200903B (es) |
| AR (1) | AR091567A1 (es) |
| AU (1) | AU2013281626A1 (es) |
| BR (1) | BR112014031282A2 (es) |
| CA (1) | CA2877619C (es) |
| HK (1) | HK1209338A1 (es) |
| IL (1) | IL236187A0 (es) |
| MX (1) | MX2014015269A (es) |
| NZ (1) | NZ703528A (es) |
| PH (1) | PH12014502863A1 (es) |
| RU (1) | RU2015102333A (es) |
| SG (1) | SG11201408511QA (es) |
| TW (1) | TWI623327B (es) |
| UY (1) | UY34880A (es) |
| WO (1) | WO2014003199A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105982867A (zh) * | 2015-02-27 | 2016-10-05 | 江苏柯菲平医药股份有限公司 | 一种h009冻干粉针及其制备方法 |
| CN104814964B (zh) * | 2015-04-16 | 2018-07-31 | 广东赛烽医药科技有限公司 | 一种抗胃幽门螺旋杆菌的药物组合物、制备方法及其应用 |
| CN106265535A (zh) * | 2015-06-23 | 2017-01-04 | 中美华世通生物医药科技（武汉）有限公司 | 富马酸沃诺拉赞冻干粉针制剂及其制备方法 |
| CN104926790B (zh) * | 2015-06-29 | 2017-07-07 | 江苏奥赛康药业股份有限公司 | 一种高纯度Vonoprazan Fumarate化合物及其中间体、杂质以及它们的制备方法 |
| CN106511344A (zh) * | 2015-09-14 | 2017-03-22 | 王虹 | 一种胃酸分泌抑制剂的新用途 |
| RU2657833C2 (ru) * | 2015-12-01 | 2018-06-15 | Общество С Ограниченной Ответственностью "Остерос Биомедика" | Стабилизированная лекарственная форма конъюгата этидроната с цитарабином и её применение |
| CN105640877A (zh) * | 2016-01-26 | 2016-06-08 | 北京阜康仁生物制药科技有限公司 | 一种含有沃诺拉赞的液体制剂 |
| CN107525877B (zh) * | 2016-06-20 | 2021-08-03 | 重庆医药工业研究院有限责任公司 | 一种采用液相色谱法分离测定依匹哌唑及其杂质的方法 |
| EA030671B1 (ru) * | 2016-07-20 | 2018-09-28 | Общество С Ограниченной Ответственностью "Остерос Биомедика" | Препарат для лечения костных поражений, вызванных злокачественными новообразованиями |
| CN107536801B (zh) * | 2017-08-18 | 2019-08-06 | 常州兰陵制药有限公司 | 氯化钙溴化钠注射液的制备工艺 |
| CN108689991B (zh) * | 2018-06-11 | 2019-12-20 | 杭州中美华东制药有限公司 | 沃诺拉赞新晶型盐及其制备方法 |
| CN110917201A (zh) * | 2019-12-02 | 2020-03-27 | 吉林省博大伟业制药有限公司 | 聚普瑞锌在制备治疗萎缩性胃炎伴随胃粘膜上皮异型增生的药物中的应用 |
| CN113350271A (zh) * | 2020-03-04 | 2021-09-07 | 广东东阳光药业有限公司 | 一种质子泵抑制剂的组合物及其制备方法 |
| AU2021293694B2 (en) * | 2020-06-17 | 2023-12-21 | Ildong Pharmaceutical Co., Ltd. | Novel Acid Secretion Inhibitor and use thereof |
| CN111943932B (zh) * | 2020-08-06 | 2023-07-14 | 四川国康药业有限公司 | 一种可以治疗消化性溃疡的3-吡啶磺酰-1-n-杂吡咯衍生物及其制备方法和用途 |
| CN116270443A (zh) * | 2022-10-27 | 2023-06-23 | 广州白云山天心制药股份有限公司 | 富马酸伏诺拉生注射液及其制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19833119A1 (de) * | 1998-07-23 | 2000-01-27 | Roche Diagnostics Gmbh | Spritzfertige Injektionslösungen enthaltend Carvedilol |
| ES2305065T3 (es) * | 2000-04-24 | 2008-11-01 | Daiichi Sankyo Company, Limited | Preparacion liquida estable que contiene sitafloxacina. |
| MY137726A (en) * | 2000-11-22 | 2009-03-31 | Nycomed Gmbh | Freeze-dried pantoprazole preparation and pantoprazole injection |
| US6310094B1 (en) * | 2001-01-12 | 2001-10-30 | Baxter International Inc. | Ready-to-use esmolol solution |
| CA2473412A1 (en) * | 2004-07-08 | 2006-01-08 | Laboratoires Omega Ltee | Liquid pharmaceutical injectable formulation of octreotide |
| EP2336107B1 (en) | 2004-09-30 | 2015-09-23 | Takeda Pharmaceutical Company Limited | Proton pump inhibitors |
| US20070191306A1 (en) * | 2005-08-17 | 2007-08-16 | Bristol-Myers Squibb Company | FACTOR Xa INHIBITOR FORMULATION AND METHOD |
| PL1919865T3 (pl) * | 2005-08-30 | 2011-09-30 | Takeda Pharmaceuticals Co | 1-heterocyklilosulfonylo, 2-aminometylo, 5-(hetero-) arylo podstawione pochodne 1-h-pirolu jako kwasowe inhibitory wydzielania |
| WO2007114338A1 (ja) | 2006-03-31 | 2007-10-11 | Takeda Pharmaceutical Company Limited | 酸分泌抑制薬 |
| US8933105B2 (en) | 2007-02-28 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| US8658183B2 (en) * | 2007-08-09 | 2014-02-25 | Taigen Biotechnology Company, Ltd. | Antimicrobial parenteral formulation |
| EP3162798B1 (en) | 2007-09-28 | 2021-04-14 | Takeda Pharmaceutical Company Limited | 5-membered heterocyclic compound |
| CL2008002834A1 (es) | 2007-09-28 | 2009-09-11 | Takeda Pharmaceuticals Co | Compuestos heterociclicos de 5 miembros, composicion farmaceutica, util para el tratamiento de la ulcera peptidica, sindrome de zollinger-ellison, gastritis, esofagitis por reflujo, enfermedad sintomatica por reflujo gastroesofagico, esofago de barrett, cancer gastrico, hiperacidez gastrica o ulcera debido a estres posquirurgico. |
| US9186411B2 (en) * | 2008-07-28 | 2015-11-17 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition |
| AU2009284867B2 (en) | 2008-08-27 | 2014-08-28 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| NZ595890A (en) | 2009-03-26 | 2013-09-27 | Takeda Pharmaceutical | Pyrazole compound |
-
2013
- 2013-06-26 CN CN201910298076.XA patent/CN110200903B/zh active Active
- 2013-06-26 KR KR1020157002034A patent/KR102206928B1/ko active IP Right Grant
- 2013-06-26 NZ NZ703528A patent/NZ703528A/en not_active IP Right Cessation
- 2013-06-26 WO PCT/JP2013/068192 patent/WO2014003199A1/en active Application Filing
- 2013-06-26 TW TW102122662A patent/TWI623327B/zh active
- 2013-06-26 AR ARP130102255 patent/AR091567A1/es unknown
- 2013-06-26 CN CN201380044649.7A patent/CN104582687A/zh active Pending
- 2013-06-26 SG SG11201408511QA patent/SG11201408511QA/en unknown
- 2013-06-26 UY UY0001034880A patent/UY34880A/es not_active Application Discontinuation
- 2013-06-26 CA CA2877619A patent/CA2877619C/en active Active
- 2013-06-26 MX MX2014015269A patent/MX2014015269A/es unknown
- 2013-06-26 US US14/407,174 patent/US20150165027A1/en not_active Abandoned
- 2013-06-26 JP JP2014561221A patent/JP6216338B2/ja active Active
- 2013-06-26 EP EP13737879.0A patent/EP2866788B1/en active Active
- 2013-06-26 CN CN201911035338.XA patent/CN110917130A/zh active Pending
- 2013-06-26 BR BR112014031282A patent/BR112014031282A2/pt not_active IP Right Cessation
- 2013-06-26 RU RU2015102333A patent/RU2015102333A/ru not_active Application Discontinuation
- 2013-06-26 AU AU2013281626A patent/AU2013281626A1/en not_active Abandoned
-
2014
- 2014-12-11 IL IL236187A patent/IL236187A0/en unknown
- 2014-12-22 PH PH12014502863A patent/PH12014502863A1/en unknown
-
2015
- 2015-10-15 HK HK15110093.8A patent/HK1209338A1/xx unknown
-
2022
- 2022-12-16 US US18/082,799 patent/US20230143246A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI623327B (zh) | 2018-05-11 |
| NZ703528A (en) | 2016-08-26 |
| PH12014502863A1 (en) | 2015-02-23 |
| CA2877619A1 (en) | 2014-01-03 |
| CN110200903A (zh) | 2019-09-06 |
| KR20150023883A (ko) | 2015-03-05 |
| BR112014031282A2 (pt) | 2017-06-27 |
| UY34880A (es) | 2014-01-31 |
| TW201406399A (zh) | 2014-02-16 |
| SG11201408511QA (en) | 2015-01-29 |
| HK1209338A1 (en) | 2016-04-01 |
| CN104582687A (zh) | 2015-04-29 |
| US20150165027A1 (en) | 2015-06-18 |
| EP2866788A1 (en) | 2015-05-06 |
| CN110200903B (zh) | 2022-07-29 |
| US20230143246A1 (en) | 2023-05-11 |
| WO2014003199A1 (en) | 2014-01-03 |
| IL236187A0 (en) | 2015-01-29 |
| JP6216338B2 (ja) | 2017-10-18 |
| KR102206928B1 (ko) | 2021-01-22 |
| MX2014015269A (es) | 2015-02-20 |
| RU2015102333A (ru) | 2016-08-20 |
| JP2015521986A (ja) | 2015-08-03 |
| AU2013281626A1 (en) | 2015-01-22 |
| CA2877619C (en) | 2020-09-22 |
| EP2866788B1 (en) | 2020-12-16 |
| CN110917130A (zh) | 2020-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091567A1 (es) | Preparacion liquida, metodo, kit de inyeccion | |
| PE20141585A1 (es) | Composicion farmaceutica estabilizada a base de un compuesto no petidico | |
| ECSP19003047A (es) | Nuevos análogos de urocortina-2 modificados con ácido graso para el tratamiento de diabetes y enfermedad renal crónica | |
| PH12015501620A1 (en) | Pharmaceutical composition with improved bioavailability | |
| BR112016024509A2 (pt) | composições detergentes de dose unitária | |
| PE20091960A1 (es) | Compuestos de insulina lispro pegilada | |
| AR085155A1 (es) | Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen dichos compuestos | |
| HN2011001445A (es) | Derivados de acido tetramico sustituidos alcoxi/alquilespirociclicamente geminales | |
| NZ712270A (en) | Pharmaceutical composition of s-ketamine hydrochloride | |
| BR112015002153A2 (pt) | composto heterocíclico parcialmente saturado contendo nitrogênio | |
| UY32816A (es) | Formulación farmacéutica a base de 1-[2-(2,1,3-benzotiadiazol-5-ilamino)-6(2,6-diclorofenil)-pirido[2,3-d] pirimidin-7-il]-3-tert-butil-uréa | |
| AR102463A1 (es) | Inhibidor de cinasa aurora a | |
| UY29652A1 (es) | Mezclas fungicidas a base de bifenilamidas de ácido pirazolcarboxílico 3-monosustituidas | |
| CL2009001133A1 (es) | Procedimiento para preparar particulas que contienen dos compuestosw agroquimicos activos en froma amorfa y no mas de 5% en peso de inhibidores polimericos de la cristalizacion y donde uno de esos compuestos inhibe la cristalizacion del otro; particulas obtenidas con dicho procedimiento y fromulacion agroquimica que la contiene. | |
| BR112012014721A2 (pt) | composição de hormônio do crescimento | |
| CO6612226A2 (es) | Tableta | |
| EA201201662A1 (ru) | Дизамещенные тетрагидрофуранильные соединения в качестве антагонистов брадикининового рецептора в1 | |
| RU2008112989A (ru) | Фармацевтический состав для инъекций | |
| CO6150180A2 (es) | Sales de bencimidazolil-piridil-eteres y formulaciones de las mismas | |
| EA201400215A1 (ru) | Антраниламидные соединения и их применение в качестве пестицидов | |
| BR112012022136A2 (pt) | composição de matéria, adiponitrila, poliamida, caprolactama, e, poliéster | |
| EA201100104A1 (ru) | Фармацевтическая композиция, содержащая статин | |
| CR9567A (es) | Formulacion de liberacion prolongada de principios activos que presentan una solubilidad dependiente del ph | |
| WO2006111853A3 (en) | Stable solid dosage forms of acid labile drug | |
| ATE538098T1 (de) | Verfahren zum herstellen von 5-fluor-1,3-dialkyl- 1h-pyrazol-4-carbonsäurechloriden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |